Australia Cardiac Marker Testing Market (2026-2031)
The Australia Cardiac Marker Testing Market was valued at $46 Million in 2026 and projected to reach to $76 Million by 2031, representing a compound annual growth rate of 10.6%. Australia's cardiac marker testing market is positioned for sustained growth through 2031, supported by rising cardiovascular disease incidence, an aging population, and increasing healthcare expenditure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Australia Cardiac Marker Testing Market Trends and Insights
- This expansion in Australia reflects increasing demand for rapid and accurate cardiac diagnostics driven by rising cardiovascular disease prevalence and aging demographics across the country.
- Australia's healthcare infrastructure and emphasis on early disease detection position the nation as a key market for advanced cardiac biomarker testing solutions. The cardiac marker testing sector in Australia is benefiting from technological advancements in point-of-care testing and high-sensitivity troponin assays.
- Australia's regulatory environment and reimbursement policies support the adoption of innovative diagnostic platforms, enabling healthcare providers to enhance patient outcomes through faster turnaround times.
- Between 2026 and 2031, Australia is expected to see increased investment in laboratory automation and multiplex testing capabilities, further accelerating market penetration across hospitals, diagnostic centers, and primary care settings throughout the country..
Key Market Statistics
- CAGR (2026-2031) 10.6% CAGR
- Market Size, 2026 ~USD 46 Million
- Forecast, 2031 ~USD 76 Million
- Country Australia
Australia Cardiac Marker Testing Market Overview
Market Valuation Growth :
Australia's cardiac marker testing market is valued at $46.0 million in 2026 and is projected to reach $76.0 million by 2031, demonstrating strong market expansion driven by healthcare infrastructure investments and diagnostic adoption.
Robust CAGR Performance :
The Australian market is growing at a CAGR of 10.6% from 2026 to 2031, outpacing the global average of 10.3%, indicating accelerated regional demand for cardiac diagnostic solutions.
Aging Population Dynamics :
Australia's aging demographic profile is driving increased cardiovascular disease prevalence, creating sustained demand for rapid cardiac marker testing across hospitals, diagnostic centers, and primary care facilities.
Healthcare System Modernization :
Australian healthcare providers are increasingly adopting advanced cardiac biomarker assays and point-of-care testing technologies to improve patient outcomes and reduce diagnostic turnaround times in emergency and clinical settings.
Australia Cardiac Marker Testing Market Dynamics
- The adoption of high-sensitivity troponin assays and multiplex testing platforms is accelerating across Australian hospitals and diagnostic laboratories, driven by clinical guidelines emphasizing rapid rule-out protocols for acute coronary syndromes. Key growth drivers include expanding private diagnostic networks, government healthcare initiatives, and growing awareness of early cardiac risk stratification.
- Investment in pathology infrastructure and point-of-care testing capabilities will further enhance market penetration across regional and metropolitan areas, positioning Australia as a significant growth market within the Asia-Pacific cardiac diagnostics landscape..
Related Ecosystem
In Vitro Diagnostics
Medical Devices
Key Takeaways
- Australia's cardiac marker testing market will grow from $46.0M (2026) to $76.0M (2031) at a 10.6% CAGR.
- Rising cardiovascular disease prevalence and aging populations are primary growth drivers in Australia.
- Australia's advanced healthcare infrastructure supports adoption of high-sensitivity troponin and point-of-care testing technologies.
- Laboratory automation and multiplex testing capabilities are expected to expand significantly across Australian diagnostic facilities through 2031.
Cardiac Marker Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | OTHER CARDIAC BIOMARKERS (Biomarker Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 10.3% from 2026 to 2031 |
| Largest Segment | SINGLEPLEX ASSAY (Assay Format) |
| Market Size Base Year (Billions) | ~USD 5.55 (2026) |
| Revenue Forecast (Billions) | ~USD 9.06 (2031) |
| Segments Covered | Product, Technology, Type, Indication, Biomarker Type, Point Of Testing, Assay Format, End User |
Australia Cardiac Marker Testing Market Report Segmentation
8 segment dimensions are covered across the global market.
By Product
- Instruments
- Reagents & Kits
By Technology
- Clinical Chemistry
- Immunoassay
- Immunoassays
By Type
- Chemiluminescence
- Contract Testing Laboratories
- Elisa
- Hospital Laboratories
- Immunofluorescence
- Lateral Flow Immunoassay
- Reference Laboratories
By Indication
- Acute Coronary Syndrome
- Atherosclerosis
- Congestive Heart Failure
- Ischemia
- Myocardial Infarction
By Biomarker Type
- Brain Natriuretic Peptide
- Creatinine Kinase-Mb
- High-Sensitivity C-Reactive Protein
- Homocysteine
- Myoglobin
- Other Cardiac Biomarkers
- Troponin I & T
By Point Of Testing
- Lab Tests
- Poc Tests
By Assay Format
- Multiplex Assay
- Multiplex Assays
- Singleplex Assay
- Singleplex Assays
By End User
- Academic Institutes
- Laboratory Testing Facilities
- Point-Of-Care Testing
AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC INSTITUTES | 5.3 | 5.4 | 5.9 | 6.4 | 7.1 | 7.8 | 8.6 | 9.5 | 10.2 |
| LABORATORY TESTING FACILITIES | 45.2 | 45.6 | 49.2 | 53.4 | 58 | 63.4 | 69.4 | 76.1 | 9.1 |
| POINT-OF-CARE TESTING | 15.9 | 16.4 | 18 | 19.9 | 22.1 | 24.6 | 27.5 | 30.7 | 11.3 |
| TOTAL | 66.4 | 67.3 | 73.1 | 79.7 | 87.2 | 95.8 | 105.5 | 116.4 | 9.8 |
Target Audience
- In Vitro Diagnostics Manufacturers : IVD companies developing cardiac marker assays and testing platforms need Australia-specific market data to assess commercial viability, regulatory pathways, and competitive positioning for product launches and market expansion.
- Pathology Laboratory Networks : Australian diagnostic laboratories and pathology providers require market insights to optimize testing portfolios, invest in high-sensitivity assay technologies, and align service offerings with growing cardiac diagnostic demand.
- Hospital and Healthcare Systems : Hospital networks and integrated healthcare providers need market intelligence to justify capital investments in cardiac marker testing infrastructure, point-of-care devices, and laboratory automation systems.
- Medical Device and Equipment Suppliers : Suppliers of laboratory analyzers, point-of-care testing devices, and diagnostic equipment require Australia market data to identify procurement opportunities and develop region-specific product strategies.
- Healthcare Investors and Consultants : Private equity firms, healthcare consultants, and investment advisors need detailed Australian market analysis to evaluate acquisition targets, assess growth potential, and guide strategic investments in diagnostic companies.
Key Companies in the Australia Cardiac Marker Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ABBOTT LABORATORIES | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing hardware, consumables, and services),Life Sciences (instruments, reagents, and genomic medicines),Diagnostics (clinical instruments, consumables, and software), |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| THERMO FISHER SCIENTIFIC | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BIO-RAD LABORATORIES | United States | Public Company | Life Science,Clinical Diagnostics, |
| BIOMéRIEUX SA | France | Public Company | Clinical microbiology (culture media, VITEK, VITEK MS, API, ETEST, BACT/ALERT),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EPISEQ),Immunoassay and sepsis (VIDAS, Hybiome CLIA), |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (needles, syringes, vascular access, sharps safety),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems), |
| DIASORIN SPA | Italy | Public Company | Immunodiagnostics – LIAISON XL/XS infectious and GI disease panels,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX respiratory, |
| REVVITY | United States | Public Company | Diagnostics (prenatal, newborn, infectious disease, autoimmune, specialty IVD),Life science reagents, assay platforms, and genomic workflows,Instruments, imaging, detection systems, and software, |
| TOSOH CORPORATION | Japan | Public Company | Basic chemicals (caustic soda, sodium bicarbonate, calcium hypochlorite, related chlor-alkali),Petrochemicals and polymers (VCM, PVC, polyethylene, EVA, synthetic rubber, functional polymers),Polyurethanes and related intermediates (MDI, HDI, polyisocyanates, polyols, PU resins), |
| QUIDEL CORPORATION | United States | Public Company | Labs (Clinical Chemistry & Immunoassay),Transfusion Medicine,Point of Care, |
| GUANGZHOU WONDFO BIOTECH CO., LTD. | China | Public Company | Rapid test kits (COVID-19, infectious disease, fertility, drug-of-abuse, tumor markers, STD),Immunofluorescence platform (Finecare FIA Meter X2 and related assays),Chemiluminescence platform, |
ABBOTT LABORATORIES
Abbott Laboratories is a major United States-based public company founded in 1888 with approximately 115,000 employees, operating as a diversified healthcare organization.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees, operating across multiple industrial and life sciences sectors.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and healthcare solutions.
THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific is a United States-based public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.
BIO-RAD LABORATORIES
Bio-Rad Laboratories is a United States-based public company founded in 1952 with 7,450 employees, specializing in life science research and clinical diagnostics products.
BIOMéRIEUX SA
bioMérieux SA is a French public company founded in 1963 with 14,894 employees, focused on in vitro diagnostics and microbiology testing solutions.
BECTON, DICKINSON AND COMPANY
Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees, specializing in medical devices, diagnostics, and biosciences.
DIASORIN SPA
DiaSorin SpA is an Italian public company founded in 1968 with 3,242 employees, specializing in in vitro diagnostics and immunodiagnostic solutions.
REVVITY
Revvity is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.
TOSOH CORPORATION
Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees, operating across specialty chemicals, pharmaceuticals, and diagnostics sectors.
QUIDEL CORPORATION
Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees, specializing in rapid diagnostic testing solutions.
GUANGZHOU WONDFO BIOTECH CO., LTD.
Guangzhou Wondfo Biotech Co., Ltd. is a Chinese public company founded in 1992 with 2,443 employees, focused on in vitro diagnostic products and solutions.
Reasons to Buy this Report
- Market-Specific Growth Projections : Access detailed forecasts showing Australia's cardiac marker testing market expanding from $46M to $76M by 2031, enabling accurate business planning and investment decisions tailored to regional growth trajectories.
- Competitive Landscape Intelligence : Understand the competitive positioning of diagnostic providers, laboratory networks, and testing platforms operating within Australia's healthcare system to identify partnership and expansion opportunities.
- Regulatory and Clinical Insights : Gain insights into Australian healthcare regulations, pathology accreditation requirements, and clinical adoption patterns for cardiac marker testing technologies specific to the local market.
- Demographic and Disease Trend Analysis : Leverage data on Australia's aging population, cardiovascular disease prevalence, and regional healthcare disparities to target high-opportunity segments and geographic markets.
- Strategic Market Entry Planning : Develop informed go-to-market strategies for diagnostic companies, reagent manufacturers, and healthcare IT providers seeking to establish or expand operations in the Australian cardiac diagnostics sector.
Frequently asked questions
What is the current size of Australia's cardiac marker testing market?
Australia's cardiac marker testing market was valued at $46.0 million in 2026 and is projected to reach $76.0 million by 2031.
What is the expected growth rate for cardiac marker testing in Australia?
Australia's cardiac marker testing market is expected to grow at a compound annual growth rate (CAGR) of 10.6% from 2026 to 2031.
What factors are driving growth in Australia's cardiac marker testing market?
Key drivers include rising cardiovascular disease prevalence, aging demographics, technological advancements in point-of-care testing, and supportive regulatory policies in Australia.
Which cardiac marker testing technologies are gaining adoption in Australia?
High-sensitivity troponin assays, point-of-care testing platforms, and multiplex testing capabilities are experiencing increased adoption across Australian healthcare facilities.
How is Australia's healthcare infrastructure supporting cardiac marker testing expansion?
Australia's advanced healthcare system, favorable reimbursement policies, and emphasis on early disease detection are enabling rapid adoption of innovative cardiac diagnostic solutions.
RESEARCH METHODOLOGY
The objective of the study is to analyze the key market dynamics, including drivers, opportunities, restraints, challenges, and strategies of key players. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The competitive landscape of the cardiac marker testing market analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches are used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation have been used.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
BREAKDOWN OF PRIMARY INTERVIEW PARTICIPANTS
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = > USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
|
COMPANY NAME |
DESIGNATION |
|
Abbott Laboratories (US) |
Sales Manager |
|
F. Hoffmann-La Roche AG (Switzerland) |
Product Manager |
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the sizes of various market subsegments. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the cardiac marker testing market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Cardiac marker testing refers to the measurement and quantification of biological parameters, such as enzymes, hormones, and proteins that are released into the bloodstream or show altered levels in response to cardiac conditions. These tests serve as indicators of the heart's physiological and pathophysiological status and are used for the early detection, risk stratification, and monitoring of cardiovascular diseases, including acute coronary syndrome (ACS), acute myocardial infarction (AMI), cardiac ischemia, and congestive heart failure (CHF).
Key Stakeholders
- Product Manufacturers, Distributors, and Suppliers
- Diagnostic Laboratories and Point-of-care Testing Centers
- Research Laboratories and CROs
- Ambulatory Testing Centers
- Contract Testing Laboratories
- Academic Universities and Medical Research Centers
- Research & Development (R&D) Centers
Report Objectives
- To define, segment, and forecast the cardiac marker testing market by product, technology, indication, biomarker type, point of testing, assay format, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
- To study the impact of AI on the market, along with the macroeconomic outlook for each region
Available customizations:
MarketsandMarkets offers the following customizations for this market report.
Country Information
- Additional country-level analysis of the cardiac marker testing market
Company profiles
- Additional five company profiles of players operating in the cardiac marker testing market.
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the cardiac marker testing market
Get the Full Cardiac Marker Testing Market Report
Full forecast, segment splits, and company analysis for all Cardiac Marker Testing Market.
- US Cardiac Marker Testing Market
- Canada Cardiac Marker Testing Market
- UK Cardiac Marker Testing Market
- Germany Cardiac Marker Testing Market
- France Cardiac Marker Testing Market
- Italy Cardiac Marker Testing Market
- Spain Cardiac Marker Testing Market
- China Cardiac Marker Testing Market
- Japan Cardiac Marker Testing Market
- India Cardiac Marker Testing Market
- South Korea Cardiac Marker Testing Market
- Brazil Cardiac Marker Testing Market
- Mexico Cardiac Marker Testing Market
- Rest Of Europe Cardiac Marker Testing Market
- Rest Of Asia Pacific Cardiac Marker Testing Market
- Rest Of Latin America Cardiac Marker Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report